HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ChromaDex Hits Consumer Brand Marketing Sweet Spot With Former Nestle Executive In Charge

Executive Summary

Tru Niagen supplement firm names Fadi Karam CMO a little more than a month after it announced a distribution deal to put its nicotinamide riboside supplement on shelves at US Walmart stores.

You may also be interested in...



ChromaDex Promotes Gerber To CFO

Gerber was serving as interim CFO. She has more than 20 years’ experience in investment management and investor relations and finance, including strategic planning, operational efficiency programs and capital market transactions.

Split Decision In Breach-of-Contract Battle Of Litigation War Between ChromaDex, Elysium

California federal court jury found both breached contracts: Elysium failed to pay for nicotinamide riboside and pterostilbene it ordered and received, while ChromaDex violated pricing provision in supply agreement.

ChromaDex To Offer Lower-Dose Tru Niagen At Lower Price In US Walmart Stores

ChromaDex expects to expand target market for Tru Niagen while also expanding sales through stocking product at US stores of world’s largest retailer. It also will expand the range of package sizes and prices for its supplement as the product it provides Walmart will be at a lower dose than what it offers for sale online.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel